Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Atezolizumab in Triple Negative Breast Cancer: NCT05774886 Clinical Landscape Report 2026
16 October 2026
NCT05774886 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BSI-585 in Liver Cancer: NCT05788484 Clinical Landscape Report 2026
16 October 2026
NCT05788484 clinical landscape for Liver Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FLUORODOPA F-18 in Glioblastoma: NCT05781321 Clinical Landscape Report 2026
16 October 2026
NCT05781321 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oditrasertib in Amyotrophic Lateral Sclerosis: NCT05795907 Clinical Landscape Report 2026
16 October 2026
NCT05795907 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CTX-131 in Pancreatic adenocarcinoma: NCT05795595 Clinical Landscape Report 2026
16 October 2026
NCT05795595 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) in Recurrent Low Grade Astrocytoma: NCT05789394 Clinical Landscape Report 2026
16 October 2026
NCT05789394 clinical landscape for Recurrent Low Grade Astrocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Epidermal growth factor receptor tumour activated T-cell engager therapy (Janux Therapeutics/Merck & Co) in Pancreatic Ductal Adenocarcinoma: NCT05783622 Clinical Landscape Report 2026
16 October 2026
NCT05783622 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Tislelizumab in Advanced Malignant Solid Neoplasm: NCT05789069 Clinical Landscape Report 2026
16 October 2026
NCT05789069 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Sodium pentaborate pentahydrate in Advanced Renal Cell Carcinoma: NCT05798455 Clinical Landscape Report 2026
16 October 2026
NCT05798455 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avutometinib/Defactinib in Recurrent Glioblastoma: NCT05798507 Clinical Landscape Report 2026
16 October 2026
NCT05798507 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Itraconazole in Amyotrophic Lateral Sclerosis: NCT05797753 Clinical Landscape Report 2026
16 October 2026
NCT05797753 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT05806060 Clinical Landscape Report 2026
16 October 2026
NCT05806060 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.